Cite

HARVARD Citation

    Gatti‐Mays, M. et al. (2020). A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer. Oncologist. pp. 1013-e1824. [Online]. 
  
Back to record